Novavax extends manufacturing agreement with South Korea’s SK bioscience
Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Dec 21
Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…
23 Dec 21
The US regulator’s decision is based on the data from the Phase 2/3 EPIC-HR trial, which enrolled non-hospitalised…
23 Dec 21
The acquisition will enable Novartis to add Gyroscope’s investigational gene therapy, GT005, to its portfolio
22 Dec 21
The acquisition of Amunix will enable Sanofi to discover and develop advanced T-cell engagers (TCE) and cytokine medicines…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 21
The sBLA submission was based on positive results from the Phase 3 trial, in which Ultomiris significantly improved…
21 Dec 21
The drug, administered six times per year, showed superior efficacy to daily oral PrEP option, in reducing the…
21 Dec 21
With the latest partnership, the Swiss drugmaker intends to expand its capabilities in the research and development of…
20 Dec 21
Tezspire is also being developed for other potential indications, including chronic obstructive pulmonary disease, chronic rhinosinusitis, chronic spontaneous…
20 Dec 21
The WHO EUL for Novavax’s Covid-19 vaccine is currently under assessment; will be completed following European Medicines Agency…
17 Dec 21
The collaboration combines Alpine's discovery platform and expertise with Horizon's drug development and commercialisation capabilities